Latest Medtech News
Archeon Medical, a Besançon, France-based developer of emergency ventilation monitoring technology, has raised $9 million (€7.5 million) in Series A equity funding. Newfund, through its HEKA fund, led the round. Eiffel Investment Group, UI Investissement (OSER BFC fund), Majycc Innovation Santé, and Karot Capital also participated. The company will use the capital to accelerate US clinical validation and its commercial efforts.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
Archeon's EOlife is a real-time feedback device that measures the volume of air delivered to a cardiac arrest patient's lungs during manual ventilation. It gives visual guidance meant to prevent both hyperventilation and under-ventilation, two common errors during resuscitation. The device holds FDA clearance and CE marking and operates in both European and US markets.
For Archeon, the round funds the evidence-building step that follows regulatory clearance. The company has previously reported results from a real-world study with a French fire and rescue service, which it says showed survival with good neurological outcomes tripled. CEO Alban de Luca said the resources will let the company generate clinical evidence at scale and make EOlife "the new global standard for emergency resuscitation."
For the broader MedTech space, the deal adds to investor interest in tools that measure and improve the quality of emergency care, an area where manual ventilation has long depended on rescuer judgment rather than objective feedback.
